Market Access Solutions for Life Sciences
Evidence-Driven Market Access for Life SciencesThrough a combination of AI tools and expert services, MadeAi streamlines and accelerates the delivery of insights and reports for Market Access teams.
MadeAi supports successful drug reimbursement, pricing approval, and market adoption, by enabling organizations to develop compelling value narratives validated by clinical evidence, real-world evidence (RWE), and health economic outcomes research (HEOR).
Discover Proven Results From Our Customer Success Stories
60%
Time Savings
90+%
Accuracy
100%
Client Satisfaction
96+%
Traceability
The Evidence Challenge Facing Market Access Teams
Modern market access decisions depend on a growing body of evidence including clinical outcomes, real-world data, economic analyses, and patient-reported outcomes. In Market Access for Life Sciences, these inputs must be integrated into clear value narratives that demonstrate clinical benefit, cost effectiveness, and differentiation from competing therapies.
However, assembling and synthesizing this evidence is often time-consuming and resource-intensive. Market access teams frequently spend months conducting systematic literature reviews (SLRs), preparing value dossiers, and continuously updating evidence packages to meet evolving requirements across multiple markets.
MadeAi helps streamline these processes by accelerating evidence discovery, synthesis, and content generation while maintaining transparency and traceability.
Accelerate Evidence Generation
Reduce the time required to gather, synthesize, and analyze literature supporting reimbursement and pricing strategies.
Strengthen Value Narratives
Transform complex clinical and economic evidence into clear, compelling value stories for payers and HTA agencies.
Reimbursement Dossier
Supporting payer access, including clinical, economic, and patient outcomes data.
Budget Impact Analyses
Estimating financial impact of product adoption for healthcare systems.
JCA Scoping & Dossier
Sharing an evidence assessment for EU-level HTA requirements including comparators, outcomes, and clinical benefit positioning.
Value Dossier
Providing a comprehensive summary of clinical, economic, and patient value for payers, HTAs, and stakeholders.
Market Access Reports
Summarizing payer policies, guidelines, and market trends impacting product access.
Patient Access Program Reports
Tracking outcomes and effectiveness of patient support programs.
Pricing Strategy Reports
Supporting pricing decisions with clinical, economic, and market evidence.
Improve Cross-Team Collaboration
Enable medical, HEOR, regulatory, and commercial teams to work from the same structured evidence foundation.
Maintain Scientific Rigor
Ensure every insight is traceable to its original source, supporting transparency and confidence in evidence submissions.
“MadeAi-LR has significantly accelerated how our market access team gathers and synthesizes evidence. Analyses that previously took weeks can now be completed in days, allowing us to prepare stronger value dossiers and payer evidence packages with greater confidence in the accuracy and traceability of the results.”
Market Access Leader
MadeAi User, Pharmaceutical Company
Case Studies & Scientific Research
Choose the Right Engagement Model
MadeAi Quick Research SaaS Subscription
- Want your internal team to manage research independently?
- Need a cost-effective solution with minimal reliance on external expertise?
AI-Enabled Research Services
- Need experts to handle your quick research?
- Prefer minimal hands-on involvement?
- Short on internal resources or time?
- Working on a critical publication or submission?
Build–Operate–Transfer
- Looking for a partner to help you customize your solution and build adoption internally?
- Need help operationalizing your research program?
- Trying to build a fully custom AI-driven research platform tailored to your organization?
Ready to accelerate Market Access workflows with MadeAi?
Book a demo to learn how MadeAi enables faster, more consistent market access decisions with AI-powered support.
FAQ
MadeAi is an AI-powered, next-generation platform for evidence synthesis, purpose-built to support pharmaceutical market access teams in generating insights, analyzing real-world evidence (RWE), and strengthening value communication. It transforms large volumes of clinical, economic, and real-world literature into structured, traceable insights that support pricing strategy, reimbursement submissions, value dossiers, and payer communications.
MadeAi accelerates evidence generation by automating literature screening, synthesis, and summarization while preserving full traceability. Market Access teams reduce months of manual work to days, enabling faster preparation of value dossiers and HTA submissions without compromising scientific rigor.
MadeAi, an AI-native platform, delivers 60% time savings, 90% accuracy, and 96% traceability for Market Access teams. It helps teams generate data-driven value narratives using real-world evidence (RWE), clinical outcomes, and health economic analyses for payer and HTA submissions.
MadeAi strengthens Value Dossiers by synthesizing complex evidence into clear, traceable narratives that demonstrate clinical benefit and cost-effectiveness. Market Access teams can quickly update dossiers across global markets with auditable outputs that support stronger Pricing and Reimbursement negotiations.
AI-powered literature review with MadeAi reduces evidence generation time dramatically while delivering regulatory-grade outputs. Teams gain faster insights for payer evidence packages, stronger differentiation from competitors, and more frequent updates to support global reimbursement decisions.
MadeAi quickly integrates Real-World Evidence (RWE) with clinical and economic data to build comprehensive value stories. Market Access professionals can synthesize RWE faster and with full transparency, strengthening submissions to HTA bodies and payers.
Yes, MadeAi helps with global Pricing and Reimbursement strategies by enabling rapid evidence synthesis and localized value narratives. Teams can maintain one traceable evidence base while adapting outputs for multiple markets and HTA requirements.
Evidence synthesis integrates clinical, economic, and Real-World Evidence (RWE) into structured insights. This is essential for HTA submissions, value dossiers, and pricing and reimbursement decisions.